When evaluating surfactants, consider the impact of cumulative volume, need for redosing, and product wastage on the total cost of surfactant therapy.
With a low volume and high rates of single-dose success, CUROSURF® (poractant alfa) may help minimize waste and reduce surfactant utilization in your NICU.1-11
CUROSURF® (poractant alfa) delivers more surfactant with less volume
More surfactant, less volume*1-6
- Initial dose of CUROSURF delivers a higher concentration of surfactant at a lower volume vs other exogenous surfactants1-6
- Less volume may improve tolerability and has the potential to reduce complications such as airway obstruction12,13
- Clinical studies have not established that lower volume results in superior efficacy or safety based on clinically relevant end points
- While clinical studies have demonstrated that phospholipids are an essential element, they have not established the quantity required for optimal surfactant efficacy
Considerations in Surfactant Selection
The natural surfactants currently approved by the FDA have been studied in clinical trials, all of which evaluated many factors. Some of these factors may be relevant to your analysis when reviewing the surfactant class.
In preparing the analysis supporting a formulary decision, comparing a drug class against just 1 or 2 criteria may not capture all related concerns spanning the course of treatment.
The considerations presented here are a selection of factors that were considered in a number of trials, analyses and recommendations. To access the latest research studies, go to PubMed.gov (http://www.pubmed.gov), a portal maintained by the National Institutes of Health.
This is not a comprehensive list, and some factors included in this list may not be relevant to all hospitals.
CUROSURF demonstrates consistently high rates of single-dose success
Single-dose success in clinical studies7-11
|CLINICAL STUDY||N*||GESTATIONAL AGE||CUROSURF (200 mg/kg)
|Dizdar EA, et al. 20117||126||Median 28 wks||88%|
|Sandri F, et al. 2010 (treatment arm)8||103||Mean 27.0 ± 1.0 wks||78%|
|Dani C, et al. 20049||27||<30 wks||74%|
|Ramanathan R, et al. 200410||293||Mean 28.7 ± 2.0 wks||73%|
|Verder H, et al. 199911||60||25-29 wks||88%|
- High rates of single-dose success limit the need to open additional vials for repeat dosing7-11
- Clinical studies have not established that fewer doses result in superior efficacy or safety based on clinically relevant end points
CUROSURF may help minimize wastage
Infants’ administration experience14
|1st DOSE VOLUME1||% INITIAL DOSES ADMINISTERED IN
UNDER FIVE MIN
|REFLUX RATE 5—15 MIN AFTER ADMINISTRATION||RECOVERY TIME AFTER ADMINISTRATION|
|2.5 mL/kg||58.9%||3.5%||81% of babies
recovered within 1 minute
- In an open-label, observational study, the low rate of reflux may have been attributed to small volumes and low viscosity14
- Low rates of reflux may help minimize drug loss, resource utilization, and the need to open multiple vials14